Initial results in the assessment of multiple myeloma using 18F-FDG PET

[1]  H. Shirato,et al.  Early Detection of Bone Marrow Involvement in Extramedullary Plasmacytoma by Whole-Body F-18 FDG Positron Emission Tomography , 2000, Clinical nuclear medicine.

[2]  S. Reske,et al.  FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  B. Maldague,et al.  Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey , 1999, British journal of haematology.

[4]  N. Shuke,et al.  Multiple myeloma evaluated with 201Tl scintigraphy compared with bone scintigraphy. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. Guermazi,et al.  Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma , 1999, British journal of haematology.

[6]  J. D. van der Walt,et al.  Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.

[7]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[9]  S. Larson,et al.  Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  M. Reiser,et al.  Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. , 1996, AJR. American journal of roentgenology.

[11]  M. Dimopoulos,et al.  Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Dimopoulos,et al.  Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. , 1992, Radiology.

[13]  M. Dimopoulos,et al.  Curability of solitary bone plasmacytoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Wasserman,et al.  Plasmacytoma. Treatment results and conversion to myeloma , 1992, Cancer.

[15]  R. Casale,et al.  Prognostic factors in multiple myeloma: a new staging system based on clinical and morphological features. , 1991, European journal of cancer.

[16]  R. Kyle.  Multiple myeloma. An update on diagnosis and management. , 1990, Acta oncologica.

[17]  F. Sim,et al.  Solitary plasmacytoma of bone: Mayo Clinic experience. , 1989, International journal of radiation oncology, biology, physics.

[18]  D. Galton,et al.  Classification and prognostic variables in myelomatosis. , 2009, Scandinavian journal of haematology.

[19]  N. Schmitz,et al.  Staging systems for multiple myeloma: a comparison , 1985, British journal of haematology.

[20]  M. Kundi,et al.  Prognostic relevance of cellular morphology in multiple myeloma. , 1984, Blood.

[21]  M. Knowling,et al.  Comparison of extramedullary plasmacytomas with solitary and multiple plasma cell tumors of bone. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  B. Durie.  Staging and kinetics of multiple myeloma. , 1982, Clinics in haematology.

[23]  S. Salmon,et al.  A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.